ストックスクリーナーアプリを入手
24.62
5.71%
-1.49
アフターアワーズ：
24.64
0.02
+0.08%
前日終値:
$26.11
開ける：
$26.11
24時間の取引高:
51,792
Relative Volume:
1.88
時価総額：
$230.47M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-13.61%
1か月 パフォーマンス:
-7.23%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$24.62
$26.85
1週間の範囲:
$24.62
$29.45
52週間の値動き範囲:
$15.80
$34.31
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
名前
Tvardi Therapeutics Inc
セクター
電話
(713) 489-8654
住所
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
TVRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
24.62 | 230.47M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-12 | 開始されました | Piper Sandler | Overweight |
| 2025-05-21 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | 開始されました | BTIG Research | Buy |
| 2024-06-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | ダウングレード | Needham | Buy → Hold |
| 2024-06-13 | ダウングレード | Stifel | Buy → Hold |
| 2023-03-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 再開されました | Canaccord Genuity | Buy |
| 2021-08-03 | 開始されました | JP Morgan | Neutral |
| 2020-04-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-29 | 繰り返されました | Laidlaw | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2019-01-15 | 開始されました | BofA/Merrill | Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Jefferies | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-12 | 再開されました | H.C. Wainwright | Buy |
| 2018-02-12 | アップグレード | Janney | Neutral → Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
すべてを表示
Tvardi Therapeutics Inc (TVRD) 最新ニュース
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga
Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - marketscreener.com
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia
Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com India
Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks
BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa
BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com
Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa
TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com
Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com
Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent
BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com
BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN
Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter
Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada
Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com
Form 8-KCurrent report - ADVFN
TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia
Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq
TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView
Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus
Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz
Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com
Cara Approves Reverse Split in Connection With Tvardi Merger - marketscreener.com
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics | CARA Stock News - GuruFocus
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com - Investing.com UK
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Conne - GuruFocus
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics approves merger and stock plans By Investing.com - Investing.com India
Cara Therapeutics approves merger and stock plans - Investing.com
Tvardi Therapeutics Inc (TVRD) 財務データ
Tvardi Therapeutics Inc (TVRD) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):